HomeCompanyTechnologyProduct CandidatesPartneringNewsContact

Kenta Biotech is a company focused on the discovery and development of fully human monoclonal antibodies for the treatment of life threatening hospital acquired infections.

Product Candidates
Nosocomial Infections
Pipeline
Products in Clinical Development
Products in Preclinical Development
KBPA101 against nosocomial infections like Pseudomonas aeruginosa
Kenta's lead product targets nosocomial infections with a high medical need
  » imprint    
PIPELINE


Under the strategic agreement with Kenta Biotech, Aridis Pharmaceuticals (USA) has acquired the entire Kenta mAb Portfolio.